Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol in Active Crohn's Disease (PRECISE 1)
NCT00152490Phase 3Completed
- Sponsor
- UCB
- Start
- Dec 2003
- Primary completion
- May 2005
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Certolizumab Pegol with Placebo (2 arms). Primary endpoint: Clinical Response (CDAI decrease >= 100 points) at 26 weeks. Started Dec 2003; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00152490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152490.